St Louis, MONCT07758270Now EnrollingIRB Ready

Multiple Sclerosis (MS) - Relapsing-remitting Clinical Trial in St Louis, MO

Access cutting-edge multiple sclerosis (ms) - relapsing-remitting treatment through this clinical trial at a research site in St Louis. Study-provided care at no cost to qualified participants.

Sponsored by Washington University School of Medicine

Quick Self-Assessment

See if you qualify for this St Louis location

Preparing your pre-screening questions…

Expert Care in St Louis

Access multiple sclerosis (ms) - relapsing-remitting specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple sclerosis (ms) - relapsing-remitting treatment provided free

Apply for This St Louis Location

Check if you qualify for this multiple sclerosis (ms) - relapsing-remitting clinical trial in St Louis, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to St Louis

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit St Louis site if eligible
  4. 4Begin participation

About This Multiple Sclerosis (MS) - Relapsing-remitting Study in St Louis

REDEFINE-MS is a research study for people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial. The study aims to better understand how remibrutinib affects inflammation in the brain and spinal cord by using PET imaging, MRI scans, blood samples, and cerebrospinal fluid (CSF) samples collected before treatment and again six months later. \[REDEFINE\_p...2026\_clean \| Word\] The main question the study is trying to answer is whether remibrutinib changes immune activity and inflammation in people with MS, and whether these changes can be measured using imaging and biological markers that may help predict future disease progression and treatment response.

Sponsor: Washington University School of Medicine

Who Can Participate

Inclusion Criteria

Capable of providing written informed consent for volunteering to undergo research procedures.
Male or female, any race
Age between 40 and 70 years of age, inclusive
Diagnosis of RMS according to revised 2017 McDonald criteria at screening 15
EDSS score of 0 to 6.5 (inclusive) at screening
Treated with ocrelizumab according to routine clinical practice and at standard dose for at least 18 months. The last administration of ocrelizumab must have occurred within 5 to 9 months prior to randomization.
Neurologically stable within 30 days prior to screening, including no MS relapse during this period.
Suitable to be switched to remibrutinib based on physician judgement or patient preference.

Exclusion Criteria

The exclusion criteria of the parent study are adapted and inherited under this section (See parent study protocol section 5.2). In addition, the following exclusion criteria apply:
Hypersensitivity to \[11C\]-DPA-713 or any of its excipients
Contraindications to PET or MRI (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate
Presence of a low affinity binding TSPO polymorphism.
Any condition that, in the opinion of the Principal Investigator or his designee, could increase the risk to the participant or limits their ability to participate (e.g., liver or kidney disease, advanced cancer)
Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in St Louis?

Yes, this clinical trial (NCT07758270) has an active research site in St Louis, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Sclerosis (MS) - Relapsing-remitting Treatment Options in St Louis, MO

If you're searching for multiple sclerosis (ms) - relapsing-remitting treatment options in St Louis, MO, this clinical trial (NCT07758270) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our St Louis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple sclerosis (ms) - relapsing-remitting specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple sclerosis (ms) - relapsing-remitting clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in St Louis, MO

See all heart attack clinical trials recruiting in St Louis — not just this study.

Browse Heart Attack Trials in St Louis →

Browse More Trials by Condition

Heart Attack TrialsMultiple Sclerosis TrialsAntiphospholipid Syndrome TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in St Louis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · St Louis, MO